VYNE Therapeutics Inc. (VYNE)

VYNE Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-28.45	-23.21	-73.33	-255.57	-95.18
Depreciation & Amortization	0	0.07	0.11	0.34	0.35
Share-Based Compensation	3.31	4.3	8.08	18.1	4.9
Other Operating Activities	-0.19	-10.36	8.77	100.05	16.54
Operating Cash Flow	-25.34	-29.2	-56.37	-137.08	-73.39
Capital Expenditures	0	0	0	-0.11	-1.02
Acquisitions	5	15.67	0	38.64	0
Change in Investments	-62.35	0	1.03	50.58	42.89
Investing Cash Flow	-57.35	15.67	1.03	89.11	41.87
Share Issuance / Repurchase	82.82	1.47	76.5	61.95	14.08
Debt Issued / Paid	0	0	-36.43	0	33.9
Other Financing Activities	-0.43	0.18	-0.29	-0.14	-0.03
Financing Cash Flow	82.39	1.65	39.78	61.81	47.95
Exchange Rate Effect	0	0	0	0	0.04
Net Cash Flow	-0.3	-11.88	-15.56	13.83	16.43
Free Cash Flow	-25.34	-29.2	-56.37	-137.2	-74.41
Free Cash Flow Margin	-5976.65%	-6121.59%	-6054.46%	-653.53%	-16797.29%
Free Cash Flow Per Share	-2.47	-9.16	-19.72	-76.18	-157.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).